Low-dose-rate brachytherapy for prostate cancer: outcomes at >10 years of follow-up
Author:
Affiliation:
1. Department of Radiation Oncology; Icahn School of Medicine at Mount Sinai; New York NY USA
2. Department of Urology; Icahn School of Medicine at Mount Sinai; New York NY USA
Publisher
Wiley
Subject
Urology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/bju.14122/fullpdf
Reference24 articles.
1. 25-Year disease-free survival rate after irradiation for prostate cancer calculated with the prostate specific antigen definition of recurrence used for radical prostatectomy;Critz;J Urol,2013
2. Modern prostate brachytherapy. Prostate specific antigen results in 219 patients with up to 12 years of observed follow-up;Ragde;Cancer,2000
3. Fifteen-year biochemical relapse-free survival, cause-specific survival, and overall survival following I(125) prostate brachytherapy in clinically localized prostate cancer: Seattle experience;Sylvester;Int J Radiat Oncol Biol Phys,2011
4. Long-term results of permanent implant prostate cancer brachytherapy: a single-institution study of 675 patients treated between 1999 and 2003;Cosset;Cancer Radiother,2016
5. Long-term outcomes and toxicity in patients treated with brachytherapy for prostate adenocarcinoma younger than 60 years of age at treatment with minimum 10 years of follow-up;Buckstein;Urology,2013
Cited by 28 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Prostate high dose-rate brachytherapy as monotherapy for low and intermediate-risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy: A 9-year update;Radiotherapy and Oncology;2024-09
2. BRD4 Inhibition as a Strategy to Prolong the Response to Standard of Care in Estrogen Receptor-Positive Breast Cancer;Cancers;2023-08-11
3. Prognostic Factors for Resolution Delay of Lower Urinary Tract Symptoms in Patients with Prostate Cancer after Low-Dose-Rate Brachytherapy;Cancers;2023-08-10
4. Langzeitauswertung der Low-dose-rate(LDR)-Brachytherapie des lokal begrenzten Prostatakarzinoms;Die Urologie;2023-05-31
5. Virtual HDR Boost for Prostate Cancer: Rebooting a Classic Treatment Using Modern Tech;Cancers;2023-03-28
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3